Trimira launches oral-cancer screening system for early diagnosis by dentists

FEBRUARY 5, 2009--Trimira LLC (Houston, TX) has introduced a small, cordless, handheld device that it says enables early detection of oral cancer. Called Identafi 3000, the device uses a three-wavelength optical illumination and visualization system to allow dental professionals to identify otherwise-invisible early cancers. This affordable device will aid in diagnosing tongue, lip and mouth cancer--afflictions that have reached epidemic levels.

FEBRUARY 5, 2009--Trimira LLC (Houston, TX) has introduced a small, cordless, handheld device that it says enables early diagnosis of oral cancer. Called Identafi 3000, the device uses a three-wavelength optical illumination and visualization system to allow dental professionals to identify otherwise-invisible early cancers. This affordable device will aid in mouth, tongue, and lip cancer screening--enabling diagnosis of afflictions that have reached epidemic levels, due in part to the lack of effective, broad-based early detection systems for oral cancer screening.

Identafi 3000 uses white, violet, and amber wavelengths of light to excite oral tissue in distinct ways. Biochemical changes can be monitored with fluorescence, while morphological changes can be monitored with reflectance. This multiple wavelength technology identifies abnormal tissue with more accuracy than the single color approaches currently on the market, according to Trimira. The ability to read metabolic and physiologic differences makes it easier to distinguish between normal and abnormal tissue. The combined system of fluorescence and reflectance uses the body's natural tissue properties as an adjunctive tool for oral mucosal examination.

Identafi 3000 is supported by a national team of trained sales representatives and is available through most major U.S. dental dealers.

Trimira LLC is a subsidiary of Remicalm LLC, a privately held medical diagnostic and imaging device company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

More information:
Trimira LLC

Posted by Barbara G. Goode, barbarag@pennwell.com.

More in Biomedicine